MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Alpha-synuclein"

  • 2019 International Congress

    Role of microRNA-153 and -223 in Parkinson disease

    M. Cressatti, W. Song, L. Jawura, J. Galindez, O. Canie, A. Velly, M. Gornitsky, H. Schipper (Montreal, QC, Canada)

    Objective: To assess the therapeutic and diagnostic potential of microRNA (miR)-153 and miR-223 in mice and humans with parkinsonism. Background: Dysregulated miRNAs play a major…
  • 2019 International Congress

    A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of Alpha-Synuclein Aggregation

    D. Stamler, M. Bradbury, C. Wong, E. Offman (Newark, CA, USA)

    Objective: To evaluate the safety, tolerability and pharmacokinetics of PBT434 in healthy volunteers. Background: PBT434 is a novel, small molecule inhibitor of alpha-synuclein aggregation. In…
  • 2019 International Congress

    Maladaptive Nigrovagal Neuronal Plasticity Causes Ascending Alpha-Synucleinopathy in a Novel Environmental Toxin Based Rat Model of Parkinsonism

    T. Subramanian, K. Le, S. Hojjatinia, K. Venkiteswaran, M. Subramanian, L. Anselmi, C. Bove, R. Travagli (Hershey, PA, USA)

    Objective: Test the hypothesis that unilateral chemogenetic inhibition of the nigrovagal pathway in the subthreshold Paraquat (P) + dietary lectin (L) exposure rat model of…
  • 2019 International Congress

    NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson’s Disease: Study Design and Status Update

    T. Simuni, B. Fiske, K. Merchant, C. Coffey, H. Matthews, R. Wyse, P. Brundin, D. Simon, M. Schwarzschild, D. Weiner, J. Adams, C. Venuto, L. Trusso, L. Baker, M. Kostrzebski, T. Ward, G. Rafaloff (Boston, MA, USA)

    Objective: To assess the safety and tolerability of nilotinib (150-300 mg once daily) in moderate/advanced Parkinson’s disease (PD). Background: Nilotinib is approved by the FDA…
  • 2019 International Congress

    The influence of gender, associated neurological disorder and motive for polysomnography (PSG) in the manifestations of REM sleep behaviour disorder (RBD)

    P. Bugalho, M. Salavisa (Lisbon, Portugal)

    Objective: To access the interrelation and relative influence of gender, associated neurological disorder and context of referral to PSG on the manifestations of  (RBD). Background:…
  • 2019 International Congress

    Long-Term Effects of LPS and Alcohol in Rats: A Model of Neuro-Degenerative Disease

    M. Schiess, M. Doursout, J. Campo, Z. Peng, A. Sundaresan, S. Umar (Lawrence, KS, USA)

    Objective: We postulate alterations of the intestinal barrier (or leaky guts) enhances inflammation, as well as the production of alpga (α)-synuclein which has characteristic pathological…
  • 2019 International Congress

    Impact of a high-fat diet on the behavior of A53T alpha-Synuclein Parkinson’s disease mice

    M. Temmel, V. Niederkofler, R. Rabl, H. Roemer, B. Hutter-Paier (Grambach, Austria)

    Objective: The aim of this project was to evaluate high-fat diet (HFD) induced behavioral alterations in the A53T alpha-Synuclein Parkinsons’s disease mouse model. Background: Besides…
  • 2019 International Congress

    Alpha-synuclein interacts with BAF complex in nucleus

    N. Sugeno, T. Hasegawa, J. Kobayashi, S. Yoshida, M. Ezura, A. Kikuchi, A. Takeda, M. Aoki (Sendai, Japan)

    Objective: This study aims to uncover the prospective partner of αS in nucleus. Background: In neuronal cells, large part of alpha-synuclein (αS) localize at presynaptic…
  • 2019 International Congress

    Preclinical efficacy of drugs identified by IBM-Watson for repurposing to treat L-DOPA-induced dyskinesia

    N. Visanji, A. Lacoste, P. Ravenscroft, S. Spangler, S. Fox, A. Lang, J. Brotchie, T. Johnston (Toronto, ON, Canada)

    Objective: To test the efficacy of 3 drugs predicted by IBM Watson for Drug Discovery (WDD) as having the potential to treat L-DOPA-induced dyskinesia (LID).…
  • 2019 International Congress

    Profiling of lipoproteins and associated lipids in serum samples from Idiopathic REM Sleep Behavior Disorder patients to identify biomarkers for Parkinson’s disease

    A. Laguna, A. Iranzo, M. Serradell, N. Amigó, O. Yanes, M. Vila (Barcelona, Spain)

    Objective: To perform a lipidomic profile in serum samples from IRBD patients collected before and after their conversion to PD and DLB, in order to…
  • « Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 51
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #25676 (not found)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Welcome to the MDS Abstracts Site
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley